<SEC-DOCUMENT>0001104659-25-002278.txt : 20250110
<SEC-HEADER>0001104659-25-002278.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110070025
ACCESSION NUMBER:		0001104659-25-002278
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250108
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Cost Associated with Exit or Disposal Activities
ITEM INFORMATION:		Material Impairments
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Passage BIO, Inc.
		CENTRAL INDEX KEY:			0001787297
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				822729751
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39231
		FILM NUMBER:		25520340

	BUSINESS ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		2678660312

	MAIL ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm252728d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:PASG="http://passagebio.com/20250108">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_PASG_passagebio.com_20250108 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20250108_20250108 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001787297 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001787297</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="pasg-20250108.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-01-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-08</xbrli:startDate>
        <xbrli:endDate>2025-01-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">&#160;</span></p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p>



<p style="font: 17pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20250108__20250108_zENyfghe1Cjc"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Pursuant to Section
13 or 15(d)</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>of the Securities
Exchange Act of 1934</b></span><b><span style="font-size: 7pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90B_edei--DocumentPeriodEndDate_c20250108__20250108_zWQ1GV8Wtez8"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">January 8, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_906_edei--EntityRegistrantName_c20250108__20250108_zplVRUpRwtx4"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000011" name="dei:EntityRegistrantName">PASSAGE
BIO, INC.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 33%"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20250108__20250108_zkx7wu4Q8QZj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 34%"><span id="xdx_90D_edei--EntityFileNumber_c20250108__20250108_zxfQhW5s4Wl7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000013" name="dei:EntityFileNumber">001-39231</ix:nonNumeric></b></span></td>
    <td style="text-align: center; width: 33%"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20250108__20250108_z9oFD53puhfb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-2729751</ix:nonNumeric></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction</b></span><br/>
    <b>of incorporation)</b></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission<br/>
    File Number)</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS Employer<br/>
    Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; width: 50%"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250108__20250108_z6iCD2QQEMld" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000015" name="dei:EntityAddressAddressLine1">One
    Commerce Square</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    <span id="xdx_906_edei--EntityAddressAddressLine2_c20250108__20250108_zMa6ACzOsK78"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000016" name="dei:EntityAddressAddressLine2">2005 Market Street, 39<sup>th</sup> Floor</ix:nonNumeric></span></span></b>
    <br/>
    <span id="xdx_90F_edei--EntityAddressCityOrTown_c20250108__20250108_zPjTfHsiDV8h"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000017" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></b></span><b>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20250108__20250108_zatPTdrQwI4"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000018" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span></b></td>
    <td style="text-align: center; width: 50%"><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20250108__20250108_z8TsDTaOvBF3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">19103</ix:nonNumeric></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of principal
    executive offices)</b></span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_909_edei--CityAreaCode_c20250108__20250108_zRMrM0Niuzx"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000020" name="dei:CityAreaCode">267</ix:nonNumeric></span></b><b>)
<span id="xdx_90D_edei--LocalPhoneNumber_c20250108__20250108_zOsIsgltyxUk"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000021" name="dei:LocalPhoneNumber">866-0311</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former name or former address, if changed
since last report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 7pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&#160;</span></p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span id="xdx_901_edei--WrittenCommunications_c20250108__20250108_zJ5Gg6Vyeul5" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td>Written
                                            communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span id="xdx_90C_edei--SolicitingMaterial_c20250108__20250108_zwgONjUG7Jme" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td>Soliciting
                                            material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20250108__20250108_z595X4ISy3n" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td>Pre-commencement
                                            communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20250108__20250108_zbdX0yjwRZ0l" style="font-family: Wingdings; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td>Pre-commencement
                                            communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>



<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center"><span id="xdx_909_edei--Security12bTitle_c20250108__20250108_zM9eIqYM7TGi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, $0.0001 Par Value Per Share</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center"><span id="xdx_905_edei--TradingSymbol_c20250108__20250108_zh03BEk1NYuf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" id="Fact000027" name="dei:TradingSymbol">PASG</ix:nonNumeric></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2pt; padding-bottom: 2pt; text-align: center"><span id="xdx_90B_edei--SecurityExchangeName_c20250108__20250108_zpeEowcAJek8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market LLC</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
    (Nasdaq Global Select Market)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #211d1e">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211d1e"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt; color: #211d1e">Emerging
growth company </span><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20250108__20250108_zJzeHFhNZcdh" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 7pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-size: 10pt; color: #211d1e">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span id="xdx_90E_edei--EntityExTransitionPeriod_c20250108__20250108_znFSnbi5x9ig" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2025-01-08" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item&#160;2.02&#160;Results of Operations and Financial Condition.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;10, 2025, the Company disclosed in a corporate presentation, among other things, that t</span>he preliminary, unaudited amount
of the Company&#8217;s cash, cash equivalents and marketable securities position as of December&#160;31, 2024 is approximately $76.8 million,
which, including the activities noted below, will enable it to fund its operating expenses and capital expenditure requirements into the
first quarter of 2027. This amount is preliminary, unaudited and may change, was prepared by management and is based on the most current
information available to management. Further, this amount is subject to completion by management of the financial statements as of and for the year ended
December&#160;31, 2024, including completion of the review procedures, final adjustments and other developments that may arise between
now and the time the financial results for this period are finalized, and completion of the audit of such financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this Item&#160;2.02 shall not
be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange
Act</i></b>&#8221;), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)&#160;of the Securities Act of
1933, as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;). The information contained in this Item 2.02 shall not be incorporated
by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific
reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.05 Costs Associated with Exit or Disposal
Activities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;8, 2025,&#160;<span style="background-color: white">the Board of Directors of&#160;</span>Passage Bio,&#160;Inc. </span>(the
&#8220;<b><i>Company</i></b>&#8221;) approved,&#160;<span style="background-color: white">and management began implementing, a restructuring
plan (the &#8220;<b><i>Restructuring Plan</i></b>&#8221;) to (i)&#160;cease its lab operations at its approximately 62,000 feet of leased
laboratory space in Hopewell, New Jersey (the <i>&#8220;<b>Laboratory Lease</b>&#8221;</i>) and (ii)&#160;reduce operating costs and better
align its workforce with the needs of its strategic research and development strategy. </span>The implementation of the Restructuring
Plan should be substantially complete by the end of the first quarter 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Restructuring Plan, the Company is reducing its overall workforce by approximately 5</span>5<span style="background-color: white">%.
Impacted employees are eligible to receive severance benefits. These severance benefits are contingent upon an impacted employee&#8217;s
execution (and non-revocation) of a severance agreement, which includes a general release of claims against the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="background-color: white">The Company
expects that the Restructuring Plan will decrease its annual operating costs by approximately $9.0 million to $11.0 million, excluding
the Company&#8217;s estimates of aggregate severance and exit costs that it will incur of approximately $2.0 million, which will be recorded
primarily in the first quarter of 2025. The cost that the Company expects to incur in connection with the Restructuring Plan is subject
to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated
due to events that may occur as a result of, or that are associated with, the Restructuring Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 2.06 Material Impairments.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with <span style="background-color: white">the
Restructuring Plan, the Company is pursuing opportunities to sublease the space at the Laboratory Lease to offset portions of its financial
obligations and is pursuing opportunities to sell laboratory equipment. As a result, the Company reassessed asset groups and evaluated
such asset groups for impairment under Accounting Standards Codification 360,&#160;<i>Long-lived assets:</i>&#160;<i>Impairment or disposal
of long-lived assets</i>, for all long-lived assets at the Laboratory Lease, which comprises primarily of right-of-use assets, leasehold
improvements and laboratory equipment. As a result, the Company expects to recognize impairment expenses for its laboratory equipment
of approximately $1.0 million to $3.0 million in the three-month period ending March&#160;31, 2025. This range is preliminary, unaudited
and may change, subject to management&#8217;s completion of the reassessment of asset groups and finalization of assumptions used in impairment
testing. Additionally, this range was prepared by management based on the most current information available to management, and is subject
to the completion by management of the financial statements as of and for the three-month period ending March&#160;31, 2025, including
completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results
for this period are finalized, and completion of the&#160;audit&#160;of such financial statements. Additionally, if the Company is successful
in entering sublease agreements or agreements for the sale of laboratory equipment in the future, additional impairments of right-of-use
assets, leasehold improvements and laboratory equipment could occur based on the economic terms included in such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The non-cash impairment expenses do not impact
the Company&#8217;s cash runway and the Company expects that its existing cash, cash equivalents, and marketable securities, including
the impacts of the Restructuring Plan, will enable it to fund its operating expenses and capital expenditure requirements into the first
quarter of 2027.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January&#160;10, 2025, the Company issued a
press release announcing the Restructuring Plan and other business updates related to its PBFT02 program. A copy of the press release
is attached as Exhibit&#160;99.1 to this Current Report on Form&#160;8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this Item 7.01, including Exhibit&#160;99.1
to this Current Report on Form&#160;8-K, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange
Act, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2)&#160;of the Securities Act. The information contained
in this Item 7.01 and in the accompanying Exhibit&#160;99.1 shall not be incorporated by reference into any other filing under the Exchange
Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b><i>PBFT02 Program Updates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January&#160;10, 2025, t<span style="background-color: white">he Company announced updated </span></span><span style="background-color: white">data
from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia with mutations in the&#160;<i>GRN
(&#8220;<b>FTD-GRN</b>&#8221;)</i> and anticipated upcoming milestones. The Company also announced the successful completion of process
development and scale-up of an improved-productivity, suspension-based manufacturing process for PBFT02 and its plans to transition to
an outsourced analytical testing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Updated interim data from FTD-GRN patients treated with Dose 1 PBFT02</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Biomarkers</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Dose 1 of PBFT02 treatment resulted in a robust and durable increase in progranulin (&#8220;<b><i>PGRN</i></b>&#8221;) expression.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>PBFT02 consistently increased cerebrospinal fluid (&#8220;<b><i>CSF</i></b>&#8221;) PGRN expression in all patients from below 3 ng/mL
at baseline to 13 &#8211; 27 ng/mL at six months (n=4) and 22 &#8211; 34 ng/mL at 12 months (n=2).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>CSF PGRN levels generally plateaued by month 6 and have remained durable through the longest available follow-up of 18 months (n=1).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Plasma neurofilament light chain (&#8220;<b><i>NfL</i></b>&#8221;) levels were 13% lower than baseline on average at 12 months (n=2)
post-treatment.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>In contrast, in untreated symptomatic FTD-<i>GRN</i> patients, plasma NfL levels are expected to increase by 29% per year, according
to published natural history data.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Plasma PGRN expression remained below healthy reference levels across all patients.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration: underline">Safety (patient follow-up up to 18 months as of December&#160;9,
2024, data cutoff)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="text-align: left; vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>In five of seven patients, all treatment emergent adverse events were mild to moderate in severity.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Two of seven patients experienced a total of three serious adverse events (&#8220;<b><i>SAEs</i></b>&#8221;). As previously disclosed,
the first treated patient experienced the asymptomatic SAEs of venous sinus thrombosis (VST) and hepatotoxicity, leading to a revised
immunosuppression regimen in all subsequent patients (1,000 mg IV methylprednisolone on days 1-3 followed by 60 mg oral prednisone through
day 60). Patient 7 also experienced the SAE of VST, which was asymptomatic and completely resolved prior to day 30 following treatment
with anticoagulants. This patient had no evidence of hepatotoxicity, immune response or other laboratory abnormalities and remains enrolled
in the clinical study.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>No evidence of clinically significant immune responses in any patient who received the revised immunosuppression regimen</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>No evidence of dorsal root ganglion toxicity, as measured by nerve conduction studies, and no complications during intra cisterna
magna administration were observed across any of the seven treated patients.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Anticipated Upcoming Milestones</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-<i>GRN</i> and FTD-<i>C9orf72</i> patients to allow for dose exploration
and support program regulatory strategy.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in the second half of 2025.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Initiate dosing of FTD-<i>C9orf72</i> patients in the first half 2025.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="text-align: left; width: 0.25in; vertical-align: top"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td><td>Plan to seek regulatory feedback on FTD-<i>GRN</i> registrational trial design in the first half of 2026.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forward-Looking Statements.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529; background-color: white">This
Current Report on Form&#160;8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not
limited to, statements related to </span><span style="background-color: white">the expected costs associated with termination benefits
and the financial impact of the restructuring and the reduction in workforce; <span style="color: #212529">the Company&#8217;s expectations
about cash runway; the Company&#8217;s expectations about the timing and execution of anticipated milestones, including the outsource
of its analytical testing model, the initiation of dosing of FTD-<i>C9orf72</i>, the timing of feedback from regulatory authorities, the
progress of clinical trials and the availability of clinical data from such trials; and the ability of our lead product candidates to
treat their respective target CNS disorders, are forward-looking statements that involve risks and uncertainties that could cause actual
results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others,
the risks identified in the Company&#8217;s filings with the SEC, including its Quarterly Report on Form&#160;10-Q for the three months
ended September&#160;30, 2024, filed with the SEC on November&#160;13, 2024, and subsequent filings with the SEC. Any of these risks and
uncertainties could materially and adversely affect the Company&#8217;s results of operations, which would, in turn, have a significant
and adverse impact on the Company&#8217;s stock price. The Company cautions you not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements
to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm252728d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><a href="tm252728d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Passage Bio,&#160;Inc. press release dated January&#160;10, 2025.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (formatted as Inline XBRL).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PASSAGE BIO,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January&#160;10, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kathleen Borthwick</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kathleen Borthwick</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OkyXvMi7kpLIIiSi2y3HWNIdmd3+Hqm3bFOiYWAYzvnOEWIkclrqBhmO87KAPbZdoxxCiTUymjN6R7Zap+BviRdtHSvj+vcHZuQZ9EwSSnnyQm+9a4tVClEylnIsJxBN0ySG2UYEXz0jU+sKjdOqAWUq2DF1rNEpfg0Je/UkQ+2rrzogW00mhTiMBvkNMoolbOmuHsRXC0WRiWDUTyByplvnXYunQ/MlYdFg6+vsQP83+AAAt0qC -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm252728d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm252728d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PASSAGE BIO ANNOUNCES INTERIM DATA FROM UPLIFT-D
STUDY IN FTD-<I>GRN</I> AND PROVIDES BUSINESS UPDATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>PBFT02 demonstrated durable, elevated CSF PGRN
levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Evaluating Dose 2, 50% lower than Dose 1, in
subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Expect to report 12-month data from Dose 1
and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H
2026</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Completed process development and scale-up
of a high-productivity, suspension-based manufacturing process for PBFT02</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Extended cash runway into 1Q 2027 by moving
to outsourced analytical testing model and reducing operating expenses, allowing for the achievement of meaningful program milestones</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PHILADELPHIA &ndash; January&nbsp;10, 2025 &ndash; </B>Passage
Bio,&nbsp;Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative
diseases,&nbsp;today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of
frontotemporal dementia (FTD) with granulin (<I>GRN</I>) mutations and anticipated upcoming milestones. The company also announced the
successful completion of process development and scale-up of a suspension-based manufacturing process for PBFT02. As the PBFT02 program
continues to advance, the company reviewed its operating needs and will transition to an outsourced analytical testing model. This action,
coupled with an associated workforce reorganization and reductions in operating expenses, extends cash runway through meaningful program
milestones into the first quarter of 2027.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased to report updated interim data from our ongoing
upliFT-D clinical trial in FTD-<I>GRN</I> patients showing that Dose 1 PBFT02 consistently increased CSF PGRN expression and that this
elevation translated to early signals of improvement in a disease progression biomarker when compared to published natural history data,&rdquo;
said Will Chou, M.D., president and chief executive officer of Passage Bio. &ldquo;Given the robust levels of CSF PGRN achieved with
Dose 1 and to support future discussions with health authorities regarding the registrational pathway, we look forward to introducing
Dose 2, which is fifty percent lower than Dose 1, for subsequent FTD-<I>GRN</I> and FTD-<I>C9orf72</I> patients. We remain focused on
advancing the upliFT-D study in each of these patient populations and look forward to sharing additional data in the second half of 2025.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm252728d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;As our PBFT02 program advances, we continue to assess our operating
needs to ensure that we can deliver on meaningful program milestones as we endeavor to bring this promising therapy to the FTD patient
community,&rdquo; Dr.&nbsp;Chou continued. &ldquo;After careful consideration, we will transition to an outsourced analytical testing
model and have restructured our organization and reduced operating expenses accordingly. Following the implementation of these actions,
we expect existing cash resources will be sufficient to fund operations into the first quarter of 2027, which will allow us to further
validate the potential of PBFT02 and determine the registrational pathway for the program. We want to thank our talented team for their
commitment and important contributions as we continue to pursue our mission of improving the lives of patients with neurodegenerative
diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Updated interim data from FTD-<I>GRN</I> patients treated with
Dose 1 PBFT02:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Biomarkers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dose
                                            1 of PBFT02 treatment resulted in a robust and durable increase in PGRN expression.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PBFT02
                                            consistently increased CSF PGRN expression in all patients from below 3 ng/mL at baseline
                                            to 13 &ndash; 27 ng/mL at six months (n=4) and 22 &ndash; 34 ng/mL at 12 months (n=2).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CSF
                                            PGRN levels generally plateaued by month 6 and have remained durable through the longest
                                            available follow-up of 18 months (n=1).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
                                            NfL levels were 13% lower than baseline on average at 12 months (n=2) post-treatment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            contrast, in untreated symptomatic FTD-<I>GRN</I> patients, plasma NfL levels are expected
                                            to increase by 29% per year, according to published natural history data<SUP>i</SUP>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plasma
                                            PGRN expression remained below healthy reference levels across all patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safety</B> (patient follow-up up to 18 months as of December&nbsp;9,
2024, data cutoff)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            5 of 7 patients, all treatment emergent adverse events (AEs) were mild to moderate in severity.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2
                                            of 7 patients experienced a total of 3 serious adverse events (SAEs). As previously disclosed,
                                            the first treated patient experienced the asymptomatic SAEs of venous sinus thrombosis (VST)
                                            and hepatotoxicity, leading to a revised immunosuppression regimen in all subsequent patients
                                            (1,000 mg IV methylprednisolone on days 1-3 followed by 60 mg oral prednisone through day
                                            60). Patient 7 also experienced the SAE of VST, which was asymptomatic and completely resolved
                                            prior to day 30 following treatment with anticoagulants. This patient had no evidence of
                                            hepatotoxicity, immune response or other laboratory abnormalities and remains enrolled in
                                            the clinical study.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            evidence of clinically significant immune responses in any patient who received the revised
                                            immunosuppression regimen.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            evidence of dorsal root ganglion (DRG) toxicity, as measured by nerve conduction studies,
                                            and no complications during intra cisterna magna (ICM) administration were observed across
                                            any of the seven treated patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm252728d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Plan
                                            to evaluate Dose 2, a 50% lower dose than Dose 1, to allow for dose exploration and support
                                            program regulatory strategy: </B>Given robust CSF PGRN expression achieved at Dose 1 and
                                            to aid future discussions with health authorities regarding the registrational study design,
                                            the company has introduced a lower dose level, Dose 2, which is fifty percent of Dose 1.
                                            Cohort 2, which consists of five FTD-<I>GRN</I> patients, will be split between the dose
                                            levels; two patients have received Dose 1 and the remaining three patients in the cohort
                                            will receive Dose 2. The study is actively enrolling for treatment at Dose 2, and following
                                            completion of Cohort 2, the company plans to continue enrollment in the optional Cohort 3
                                            (n=5).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Completed
                                            process development and scale-up of a high-productivity, suspension-based manufacturing process
                                            for PBFT02: </B>The company completed internal development of a suspension-based, GMP-ready
                                            manufacturing process for PBFT02 at 200-liter scale. This process is substantially more efficient
                                            than the current adherent-based process, with improved yield and the promise of a lower cost
                                            of goods. In addition, the company developed and aligned with FDA on the suitability of a
                                            potency assay for the release of PBFT02 for late-stage clinical studies and commercialization.
                                            These two achievements position the PBFT02 program well for late-stage development.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Extended
                                            cash runway into 1Q 2027 by moving to outsourced analytical testing model and reducing operating
                                            expenses: </B>After assessing its operating needs to support the continued advancement of
                                            the PBFT02 program, the company will transition to an outsourced analytical testing model.
                                            This transition, coupled with an associated reduction in workforce of approximately 55% and
                                            reductions in operating expenses, is expected to extend cash runway into the first quarter
                                            of 2027. The company will continue to focus on execution of the ongoing upliFT-D clinical
                                            trial in FTD-<I>GRN</I> and FTD-<I>C9orf72</I> and the advancement of its preclinical program
                                            in Huntington&rsquo;s disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>On
                                            track to initiate dosing of FTD-<I>C9orf72</I> patients in 1H 2025: </B>The company has amended
                                            the upliFT-D clinical trial protocol to include two cohorts of FTD-<I>C9orf72</I> patients
                                            to be enrolled sequentially. Each cohort will consist of up to five symptomatic FTD patients
                                            with <I>C9orf72</I> gene mutations; initially, patients will receive Dose 2 PBFT02. The protocol
                                            amendment is under review at clinical trial sites and the company remains on track to dose
                                            the first FTD-<I>C9orf72</I> patient in the first half of 2025. FTD-<I>C9orf72</I> is estimated
                                            to affect approximately 21,000 patients between the United States and Europe and there are
                                            currently no disease modifying therapies approved. Preclinical studies have demonstrated
                                            that increasing PGRN levels can slow neurodegeneration and reduce TDP-43 pathology, which
                                            underlies the disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anticipated Upcoming Milestones:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FTD-<I>GRN</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report
                                            12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seek
                                            regulatory feedback on registrational trial design in 1H 2026</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FTD-<I>C9orf72</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initiate
                                            dosing of FTD-<I>C9orf72</I> patients in 1H 2025</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm252728d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About upliFT-D (NCT04747431)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">upliFT-D is a Phase 1/2 global, multi-center, open-label clinical
trial of PBFT02 administered by single injection into the cisterna magna in patients aged 35 to 75 years with FTD-<I>GRN </I>or FTD-<I>C9orf72</I>.
The clinical trial will sequentially enroll three FTD-<I>GRN</I> cohorts and two FTD-<I>C9orf72</I> cohorts.&nbsp;Enrollment is currently
ongoing.&nbsp;The primary endpoint of the clinical trial is to evaluate the safety and tolerability of PBFT02.&nbsp;Secondary endpoints
include disease biomarkers and clinical outcome measures.&nbsp;upliFT-D is a two-year clinical trial with a three-year safety extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Passage Bio&nbsp;is pursuing several initiatives to support clinical
trial recruitment and enrollment, including a collaborative partnership with InformedDNA to provide no-cost genetic counseling and testing
for adults who have been diagnosed by their physicians with FTD.&nbsp;More information about upliFT-D&nbsp;<U>can be found here</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PBFT02</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PBFT02 is a gene replacement therapy that utilizes an AAV1 viral vector
to deliver, through ICM administration, a functional <I>GRN</I> gene that encodes PGRN. This vector construct and delivery approach aim
to elevate PGRN levels in the central nervous system to alter the course of neurodegenerative diseases. Interim clinical data from the
upliFT-D Phase 1/2 study in FTD-<I>GRN</I> participants shows that ICM administration of PBFT02 resulted in robust PGRN elevations in
the CSF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The potential clinical benefit of PBFT02 is supported by extensive
preclinical studies. In non-human primates, a single ICM administration of PBFT02 led to broad vector distribution throughout the CNS,
and robust, dose-dependent elevations in PGRN levels in CSF. An NHP study also demonstrated that AAV1 was particularly proficient at
transducing ependymal cells. In a murine FTD model, PBFT02 administration improved lysosomal function and reduced neuroinflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Passage Bio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company
on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of
cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio&rsquo;s lead product candidate,
PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal
function and slow disease progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To learn more about Passage Bio and our steadfast commitment to protecting
patients and families against loss in neurodegenerative conditions, please visit:&nbsp;<U>passagebio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm252728d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>This press release contains &ldquo;forward-looking statements&rdquo;
within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including,
but not limited to: our expectations about timing and execution of anticipated milestones, including the outsource of our analytical
testing model, the initiation of dosing of FTD-<I>C9orf72</I> patients, timing of feedback from regulatory authorities, the progress
of clinical studies and the availability of clinical data from such trials; our expectations about our collaborators&rsquo; and partners&rsquo;
ability to execute key initiatives; the financial impact of the restructuring and reduction in workforce and our expectations about cash
runway; and the ability of our product candidates to treat their respective target CNS disorders. These forward-looking statements may
be accompanied by such words as &ldquo;aim,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;forecast,&rdquo; &ldquo;goal,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;possible,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; and other words and terms of similar meaning.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements,
including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies
and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected
concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional
information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety
events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success
in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual
property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of
product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential
delays, work stoppages, or supply chain disruptions; and the other risks and uncertainties that are described in the Risk Factors section
in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the
SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made
from time to time, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stuart Henderson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Passage Bio</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">267.866.0114</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>shenderson@passagebio.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Media:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mike Beyer<BR>
Sam Brown Inc. Healthcare Communications<BR>
312.961.2502<BR>
<U>MikeBeyer@sambrown.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>i</SUP> Saracino et al, <I>J Neurol Neurosurg Psych</I> 2021;
92:1278-1288.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>pasg-20250108.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa2L2bOdzZR+WYkxtmB3bfkKTygnQH6Yry5pl2fWYfgJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:PASG="http://passagebio.com/20250108" elementFormDefault="qualified" targetNamespace="http://passagebio.com/20250108">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://passagebio.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20250108_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20250108_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>pasg-20250108_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>pasg-20250108_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://passagebio.com/role/Cover" xlink:href="pasg-20250108.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm252728d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm252728d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X /$# 2(  A$! Q$!_\0
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MUO>QW5W<7NHM%_JTNY0RK^  S].GM794F]+#6]PHHHJ1A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %+5=)L=:L'LM0@6:!B#M)(P1T((Y
M!KD1\)/#8FW[KXKG_5^<-O\ Z#G]:**:;0K)G8Z=IMGI-DEG86Z00)T1?YD]
=S[FK5%%(84444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45722843218544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PASSAGE
BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2729751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One
    Commerce Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2005 Market Street, 39th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-0311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 Par Value Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PASG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M8':W^'"]?.B0Y?W\$F$;5FS#<]CFL)2*)F0I(O9"/K'7)CI<R8&4#88#;S1
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
M  @ "S@J6JK$(A8S 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,
M_)4J'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?B
MTX'HE'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,
M9KD8M;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU
M75Z(\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M
M>CR#+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3H
MD<%U!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFH
MO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    (  LX*EHD
M'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.
M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4
M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N
MF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF*
M*I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  +
M."I:99!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0
MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>
MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[
ME.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B
M+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:
M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X
M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA
M/UY_ 5!+ 0(4 Q0    (  LX*EH'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ "S@J6IZ=:=KM
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ "S@J6IE<G",0!@  G"<  !,              ( !RP$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  +."I:"!A2_Z4$  #J$0  &
M            @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ "S@J6I^@&_"Q @  X@P   T              ( !YPP  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  +."I:EXJ[',     3 @  "P
M    @ '##P  7W)E;',O+G)E;'-02P$"% ,4    "  +."I:JL0B%C,!   B
M @  #P              @ &L$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ "S@J6B0>FZ*M    ^ $  !H              ( !#!(  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "S@J6F60>9(9 0  SP,
M !,              ( !\1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  .Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm252728d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pasg-20250108.xsd</File>
    <File>pasg-20250108_lab.xml</File>
    <File>pasg-20250108_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm252728d1_8k.htm">tm252728d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm252728d1_8k.htm": {
   "nsprefix": "PASG",
   "nsuri": "http://passagebio.com/20250108",
   "dts": {
    "schema": {
     "local": [
      "pasg-20250108.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pasg-20250108_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pasg-20250108_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm252728d1_8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://passagebio.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252728d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm252728d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://passagebio.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-002278-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-002278-xbrl.zip
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MJ%D!6LEGQ*HJT.^R$E348OO]\N:F:_%);%:;Q%\KG!&QY;]02P,$%     @
M"S@J6O(/U>19!P  V5<  !4   !P87-G+3(P,C4P,3 X7W!R92YX;6S-G%US
MXC84AN\[T__@TFM"@&Z[R2;M)&S883:[24-VM^W-CK %:")+C"0'^/>5;,SR
M8<DG-S[)14+,JX_W.;;L8TN^^&N5\NB9*LVDN&QU3TY;$16Q3)B87;:^C-M7
MX\%HU(JT(2(A7 IZV1*R]=>?/_\4V9^+7]KM:,@H3\ZC]S)NC\14OHL^DY2>
M1Q^HH(H8J=Y%7PG/W!8Y9)RJ:"#3!:>&VB^*AL^C-R>]-R1JMP'U?J4BD>K+
MPVA;[]R8A3[O=);+Y8F0SV0IU9,^B64*JW!LB,GTMK;3U>GFIRA^P9EX.G>_
M)D33R/(2^GREV67+M;MI=MD_D6K6Z9V>=CO_?+H=QW.:DC83CEM,6V4I5TM5
MN>[9V5DG_[:4'BE7$\7+-OJ=LCO;FNVW+*#?Z8EFYSKOWJV,B<G#7MM,Y%6X
M_]JEK.TVM;N]=K][LM))JX2?$U22TP<ZC=Q?&[UMJPNB-9G1"9,N9!WW=6<@
M[2YI^YH7G"LZO6Q9V<S6WWMSVCU]ZVK_=4]DU@N[:VKF]JQ6U-EK>:&HIL+D
M9F_MAKTB=&7L#D63LB+7/KQOAADGW^PPW:CM]JXLM:W9CX5RTY6R,US&>^US
M%P5Y8+;<HW/6FL8G,_G<22BSS'M]]\&1Z.<4[#_?\X:N)MHH$INR)DXFE.?U
M?[>: TFG@5Z5)!YMC=6=VE<<]FDW;%<JCJ1*J+*LR[J(BO>"=;QS;A0VC,I6
MU([GC&_C/%4R]='9D)">CNZ"LDTT0_/*MI^X/@PYF57C/)  >78Q@%:ZP2+Z
MGNI8L87C4@-V3PGDVT/E6^&M8<SEL?- 9\SUUW7%G7*IVQ@>%SQ%@.#[F"-%
MT"U2!*Z$R A_H NI:L#O*X&\?\/D7>4-"?/?&5&&*KZ&D#X2 V&_P83M<8C$
M^U$1H9GC P%^K 82_QWUPL/C$0GY>$XY=VD<$:"]O$H/Q/X')G:_SU< _N;9
MG=_MJ07.?J<($/_;UX+_R"U2!.ZI8C*QIW0%8'\D!E(_PZ3N<8C*^T8D4-I;
M*3C_P8=]8 \)]9#IF/"B1T.[38=Q5\BAR%%RSEJ;J-C_I42!H>^(H<A1TM :
MBPT#'V1*[74F.*KXU5#D* EHG<F&F=\(P\S:W??_G*63'S=.]UD?JZ",49).
MGRD4MN6=!F'<XXP0WT,EE#%*KADRA\)Y8/THPD<BH:N/=!T"?22%DD;),8/V
M4%#?*Y82M1ZSN'[0.-9"8:-DEF&#*+0?R6J46%=LRHH'@O70O46@[%'22I!=
ME!",1"S50N[<+A[(S!Z/ZX%,@D-Z34%H.%#RS1=81PG*59)87'KSYY8)V@V%
MHE(.?D:$%X" S5>"O?<R[#TX=I0\M-;F*\'>?QGV/AP[2BY::Q,3^\!^O%./
M<NEY NT50Y&CY*(U%C&!YV>:.W6OY#,KYD7543\J 46/F**&S:+N\,5)'K*W
METHH;\1TM=H<)N=[J0WA_[%%W95DM1[*'#%Q#1EM^@9C$7=WT\(WE>A  N6+
MDJM6VFD:J8NPHL2_^^XKH$!1$M J,PWSO)7NV<=<BN#]V&,5E"M*)NDSU?3
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M12$ISTFMI:QYB(3^N,7</;']+IO+*!]1MU@S&"="S[LZ$BM[@%SH7 ?:[A=
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M]^Y?SF%_X_<+]>%DJ_Y[L]D,*]];&B.K7=^9X&_PTMW&_P-02P,$%     @
M"S@J6AD^*/Y]&@  O(0  !4   !T;3(U,C<R.&0Q7V5X.3DM,2YH=&WM/6M3
MV\BRWZGB/\Q-U6XE5;;!)N0%H0ZO))P"PL7.;NVG6V-I;,]!TGAG)(CWU]]^
MS$CR@R3*DKN02W8K!%N::?6[>[I;NQ\&9Z=[ZVN['X[WC^"GP#^[@Y/!Z?'>
M[@;_A&\W_->[!Q^/_A#]P1^GQV^?C$R6OQ'=S6DN!CI53IRK&W%I4IFU^(.6
MZ"NK1T_@1KCU(MR72CO6V1NQN2-R]3EORT2/X5>KQY/\R=[NP=[QYXD>ZER\
M?MWI[FX< " 7"TM\Z]8[HMP,+EW8,%)9KBSM^&LV=-.='[A7HD;X;"=G[T7_
M\O#MDSSM;?=>]E[%W?]1GU^_;G=U.M[<[';^,QT_$?NG@[=/GOSHQP[/?,LF
MS^\*MQ?[_?[^^V-Q</)1[)^??_QT?GC<%R?G@^/+DS-QM#_8%^\N/YZ)3Q>G
M)^\&[:/UM?[@$W#9R;EX-SAJ[Y[LO;\\W]TXV8.[C\3%Y<??3HY@@8-/_9/S
MXWX?[H,UCOMW2KRO8N>...]D[^+@W6"S)V*5FLSE5N8J%G%AY3!1+:$2=4V?
M'/;?B0M P_H:?*(2)V06"R5M,A/J6L<JBY0P(V%57$2Y-IG0F9@FTJ52G(].
M!=_4$E+$VBGIE)A:,[;*.;QVJ %\>Z5L2T0FG4I81>1&3(MAHMT$?LED#A E
M8J)=;NQ,Q#*72) 'B.[C:YD4,M?96!P9P$.O);8W?Q&)N5%6Y!.9\<?=%F!P
M?<T50Z?^+.!V8D4@ "$>_WWXVMC1RYZ8PF+PO4.,R036$2-C18R+J,_3Q !%
M$<=XFRNF4V-SH-*X2"1ADBD^GCU4;'Z>JBC'1[>*'JW;:P,?YQ-B$3&R)O7X
M7%]##&B\4Z?"R9'*9X24DOD6;^DA#_<^B-YF;WL'F3G#?9Q25W4$CI2*AS*Z
M$H#C0**IOC8YL&MN-?P=*P=@XV+=#^MKL-J+!XKL0Y#-1*$V .&-0';AT4"L
MS31%_B0&BV2BVL5T?0UT@01Q'4_:<"WIA&N=SUK @FZJ,I3Z]A#40 Q;9\5(
M1B#?*!)A861A5DP/%%?'GW.5Q?!\D70388OL1LZ0^XSH_C=RU$LQG(G47,-#
MKZ_!IZ;(G2EL!'?(3":S7$?(0,J1IDA-K!+","E8_,A,E64U E(.&$4(2?SQ
M(T1?/E%"1A,-)"+Z $52)3/X>E0DK'YE*E*=P!XF4^Y^(YH-^8>3T_VCXU/X
MN2]^S6) [8[X-S"0M#/>K[O9(GDMOT6C?"&=DV.UOG:@38NO.\FBCGAZ+ETL
M_WPCP$%X_PR-4Y3HC!#O<KA!C%6F@!" MU@#T@%8,D\92+V)"N1>-'0IX!+I
M2!A/]#5<!K@NU?*-!FV4J0+$0.&"2+5K ,8;0N<ARDT,',):#!8NIC%;XE(G
MX>HF&QO<Z6*")K2[T8/K$HT^2P4Z*QU5F1EOX -/Y%;)W'/$^AHL#4R9JQ3V
M)5V%WV@IGH(N>\:P Y]D!:PNGE:>T#.1%CD9%O8$)-P4Z:EDT %+Q+4E;W7$
M '8.R).) U.59:;(D-\!*#1T$0H^LF;$:@:-%N+Q*ZI&D*9IK%8Z8M\1.CQV
MO#RLKT6 #YT5BNUI?"T!QA9=&<"WX/"H&]A# W4K,<S $# R;G2"9)  #ST%
M+I1]BX0CFC2L01Y4"V$!\JJ8R0!+ !^;2!.2;XR]@J<!K\LJ8\<@UW]5=K[T
MPAQ:G56:0I%Z<G/:*9]84XPG*[3$^EI%2E9BB(^1MBX7?X+P@=)#,J!:Z]QG
M%?)K$O]9F)W?03%:\$ 31:Q2.0]!Z(*74 D?$"X(W_K:;3*GL\5XH50";L**
M&1R\W#LD@?. X1RXM7!9@A8BL@Q5<+B1:,%/1MK2"CFPR?H:.^?$8<AL"<$.
M3\-N.3H=(&E(&%91; 8 R*\XX>)FHK(&CGCK5TMH!2&6.A:_(_<?3DS1$F>=
MHTY+(/@8(;#<HD4:P4.IJ$ ]"."-=,3\X_6T #7=$9Y6[^&:C-C-FF$!_.;#
M#[B\Q)"W<BPGZVL>O80L4_J\HP(@5_CDH+D=R0:)U43)!*6KR"?&@KP".X%W
M)VT<-#K\ILE+AGO@R8&D$Y"6EK@!96_,%>J4&[@<]P*^(6>'N"1X]S<3'4T$
MB/5(C\#E!&%$-V&5PX_::<'AK_%2\/O1$6/7?X[%.N)WA#650.#*.H'72RHL
M/$S)NBXO8F0W8!: #K )WR)#\&IB:J;HX);Z??%)W4228I5QK#UB2%@TT\HI
MX.I83&0R\HIAN^.YY#[KAW*I_VJWQ3NMDAA\ ^#(';@>:1(I6%:TVSY-M7MT
M\MM\2JF=FRE<TIOF8>WVT.2Y2=^(%_C9T-A8V?*S@P0#ARYL[DRB8P!@.44U
MS>L/NKL!>Z[8?@A:XZH]5$ B@'%*,-=!>K$"(@2SZ98UQ&P@9A@9]Y2:C7)=
M=V]L?I#U K\%K=&\WQ(\%4=Z*?@PY'DXAYX/&;#@"*ROL;."MB)SJ!;)JN"=
MH([ $0&EB_;NRP$#+(VW8)@CK]&Y-&)H6=& MH/K4^V\WK%R.A/>;0 =%M0,
M>CAI6F08&7KU((YLAS&')J1\DK@T"/LC]#8B,$WL*V9H6U@[T[-_A_,%[DT9
M7TWD-:I14/@%.H^H1!%S*STL_'+)MP)K%!FR'LFL(]Z9$)+AHVMT;-$*R^#=
MLM9EA\^!QW=#21M,::C/FCU#=M$4@^_X^8:@8@LTG*2LX1%'158"PV[?EYRT
M8)1H+<X9%8Z7L4BM]36('C3Z0K3&U.04%"1DI)GO$ FQ@C7!TU=?L)-EV.'Y
MA\S4C62HT?I=$8)S<.8S<E\4\)B_1UMF$)V77K_&."7'VY$SK!X6WD:Y1;Z?
M%M;!OW!QX$/G\?UW@[4'8<4.]C[=ZLC>YJ!25+CH0C&MW]SOQ#8]\$%P7MV/
M!7:P?W!Z+ Z/3T\O]H^.3L[?OWVR^81^[U_L'X;?_:8W.LXGN.OF+SNB*01L
MMS=7V&VRS[N#R[ -Z&I29R$+!3?B@=<NZ-EY0#8[O6V=H9LS.-K[PM?O/IX/
MZHAKCR1H_=D;T9^E0Y/PL[2=_DOQ P&64AW')@<\X;WE!E]8ZBLX6-H!.=(?
M#G[CGVY-6U4Y#U"D1<*B 7&0CRE(F?&11QF!X04+\5=G[O$V!I?X%S+$G?N?
M#YS-7CY8-F-^:<9H#0)X9+HDJ;0NJ>2A0@.\);+Q1GHJP _##%8"9K49&)A:
MWBKSGKV7U7I.?Q9T*.+$T^SM\V?$[[U>>>W6\^K:;J]V:>_9,LLCQ?]_\000
MLADEB.H^3\%.1 *<,<7\C 17EC/_>$;UHNYR8N1>';V6V3CR4TPV!I>T&13R
M6NJ$EAJ1$^ISI=U7-0)W5Q#X4:?]9*;S@H[AFS%/=68/?C7$A]VMN2/JH*$P
M1@3NM9@)6%8>$#BXO%W:WD=6^^E5Y4G6V'1"Q.AR+'8011:"$#=+IX!$B6=O
MMP0LK>7J$DKJ<_2LXL:VL_3[0#OW7O^">5HQ4]*VJH#^&VI2^I\N]O3N!OYX
M9/='S;KBSZ)+6!I^=@/Y. (/&4>@=[&J*C!W9(US<^[C#^>P'Q&I]ZGR!J-T
M\32<-E0."OR/?FSIHTA*SQRI2*5#91F>URVJHGG>XK1&5.1F-'KV&//_=.+5
MU)IL(Z^\K)D(2:G@$/JK5-DQ)1)C0!^6QUU3$/9T_]@]8S<'X*3C+<P'8UT<
MFB4'EUF=S^XN%'JX%&D8&<^1@TRSU8IJ/B3@)^>$\A9@V&I3N"6Z])$P5*@Q
MQ9H+N 3"*#S 30P$V*V&)KY,A@<O(VB?.EQ4-%5W/Q &A!) 0A"=SC!3#K$9
MT "B?O'TM_[@6</ #&,^!;N;W'S6$97%)4H&#T-2@0EF$#2>C1@\P*Z,Q1@(
M5.81:H?% <O-0'G:;6UN;HIT+$Y^$ZD"PY/ 7G&FG8&8D]S[6,Z<Z+:WO)+F
M\/4%W4,50^'ZK I9X99F8+S8!#)?>'*\Y/J@1:H (9 .@.[R]$*Z>5I1>8&O
M44QF=&:27#=U!:? BW26A>586YO^L8DVI2;Q]3BPIY%8"$K'[U2Z$WAJ(L%!
M-/72Z&90+/('L0(=3$U-!B("(!H\J1$0X6.%+SJ@<I@9FX+ZH2(&/J5"WP(D
M+[/P%)3T;"XTM9JX(G[4@K##N6F&Q7J!?,"F+]#1(_@%JW+FZ4MU6UAK%OCI
M9H)%2I'2UUX<O(YH!LBM"N61JG^/JK&Q#B3$&I.+L<S&">+VZ='E^V>BDF%0
M5RE$F'2H##HT4_::CBQ#QP3*%TAN0[N&<@Z:AO0>T(B/0V,N>\1Z)'"0,3EM
M,PD^Y1C^?GIR>/8,;&T*C!C.:]G[,6!-+#(8QQI-X9CY VWRF+)%,_L0HY5O
M* ?J/98#/98#_5.Q]*6B4L(/>CQ)L'?1_>"C^L=(^/_"-G&K WB5C7.8ONA?
ME9UELM9;1AUA<_6FW]PPUM2#YDJQ%5UF;Z@?@VMZ_=G[RCKG4-!;%4L#-(W1
M@=7(=U7VR_6RW,KU'9%GZ!V82%=6"5,87*,-)?I:XBMUPY@.(Y1TFD%Q:"98
M!ETN[$^M*;@=82'VK8GVLN(,'(P<_I'?*%^2'3<NRN!DYH[(;TR5&/ 'H-Z[
MK9=O3\+!*%/%*E7=Y4N-(WJN9E#0$_D-/;ZY0\5717,+QC4&D1PZE3U590@8
M.!.%#" MH\2FYQ_U5I>*1'66P<9#*LXKJ]L8IE#-3WU!4\^F?HFMAFF [.WV
MCS\)?C0F_Y0Q*1LW&ROR;VB]^NXFSV; 5*U;;$3J#651V9A*!8_4C5"#>66'
M6$N\/[MH@SS'#9-57^LL0]70V]QL@[($S4ZX"LDA?RW\$S-W6,:J*1.0&CRY
M#/6\3:V+](JPL):SVQ,\.<H]ZOVF+39[OA,H%C/TVDLER\7:BC'%)BDR30M.
MX.:Q,;'KB).L; R9UV6>*HIW)B$+[6WOCO8QW4CQ8Z%S.=2 0 HI&QZP4;5R
M-,/"]UKYL574[56K"<1OL"2GS;V><VFND$##ZF.PNT E7_S=T.@.J+P;C5VM
M$]=A780O3E]J0(1('&S3 FPU9G[4TC^ME@XMXPU=B*_VEXN_U5[>,"GFNR!8
M1W.O!G>@4#YJ1<-LK46/-85O^ @=+66G<A,PEN5J7@]]?X=N4_G7KK8/CC>Y
MM:-W;G1*U=Z+"G *#_%9IY*.-;:W?VD>#7V](UB[LG:&0DEBQF7N6NHI:6PC
MJ$MXKA^<J%'OW:#^1;0&ODVT[)4I&^"76G ;\L<M_;JW]%@&,SG/DL3.$+.6
MEJ/LEFX""@#QH<!''^<F^]4Z["YQH4'W4=O_M-K^8]/TCL7D,!6J@2[!) ]$
MWZ2I1U]J"^:Q,]2!N^PW8S9"IM]A=.9:B1>ZX$$*<A.9Q!?5)47,'A 'ZNXK
M\#9.\@Q5=;SI#\/)J>Z(8TEI#@J(@XK!E ="P'5&E/=8*#;\3DA(H2\\$]9^
M5W,R=CSE +96O>%L*1513J@8L&=.V&QX&(-$Y02!$P70U_JI%1B<+- +3)/W
M=N>'7/#1,0\78,YKGNZIK,7M) \Y#+YNKF5\U5UHI\ @HS'\CHS@:(2]E?,&
MM<=%$"5)ZAFN3T R8*P^T- CZ;BP8#X#OBR-DFCHL7&@!CMGIIS$ -Z%'LVJ
M=EF*0*8<K'7$1<W*A/B$LF;UJ6V-X\8\%+W2E)A:TP)V 3M,#"]T0LXUOXK!
MT47[^18U>IK$C&<^L]@,#&+.!)^'$HK_C-F[D\.8_=H(G$]A!,Y9V2W]$+HH
MY[VAQ[.DA^]JK-CA4C4_TKEUJI[X.T/U'HM.]OI*736-Y%:.'EPXKEJ>/"AX
M\.##TZO+/L"C8OHI9>'$!S;-Y*%I%/3P1. ;JI"V'JN0'JN0_C''=VB*O$H'
M/#T_'&P^?PG_;76?W7>GMX0:S_QK8S7'B1G*I 71>Y+K-L]U;6'>-&LG<JB2
M6MZ136UM,HZOK%2^SA/5$\V5^(\*Z5V?1UTHS,2)V4%? 1?'8FL;8]:7V]2'
MZ.M6*A==H(8S=H7:ZZRO#>J%VPPA91KJ&1*?-_%U%0N9T)"MH3CWQJQ2KOX2
M/Z[IN%:4X*H8=WW-IVS]99S3@-#;XO[Q%+[*0W)W<9RBFZMIHI/!RL/,30(Q
M:75*Z),FO$N?YL_5]W#K:R$9%4+NTD?U9WUA=^!FB-Y4*-8-#SC/*H"3-I)E
M&<N8V&><\@4>9DJH^RDB]U<>:B,8>6T\ML9)2FACJ1.*\N9DJ&EX4NWX9E$D
MK(IL49O=5)6MM'QBD"8( A\EOHL!<V!3:?,,:#+14T;F20;V(U7QT?D^->#B
M_":@8F;:>$1=SNB-3)%14_J8V2.,]L*C5!F#&#LJHJ>LR1#3.[$&J<-&(A12
MFC8EII.9@QA>9I6P>>*?X0F])DA\'F1.Z7DZ?-K#S,D0)RX4U.1CU>[&I[U[
M3?%2@8=QV_=;87LE2S)(^56KIN"P\)E,.6D.<UM%#KKA+\K:B?W]W[KB6B/S
M7H,6-I9F;OM!=ZVR<>GD\&RA,!Y+*$=%%OFPJJ8@:7/:"%PP Y$69=!\I0=O
M0@EG&B3GQZ71=C/.ZV%R6NJ4 /%O69C+P87R-H4U_ EU"U #V@QL1LJEF[FR
M/F=;6"YM6)I<)LK!92!''*67"FMNM'1MJFUE!<LAH4NU@99S76&TK6-,+..O
M9A?KDY=\[2?7?88IMH[:D_"!#OOO[K7,#.:&XI4('0+:1SJO/3-5^DS]2.]A
M:01PHMQT.:5+A3.9R=J3 F!@,YG37/?@1'P1P0F?W Z!M^+ @3%>Z*?D!39'
M82<LG_=;_%8$)D>+$OSM6$WQ1 @;(^N4661.I)'8S\3YAPO/)]2V-_<:$6(*
MDCWLU6.N*1*:3@P2$,87RAPM!BA=7WI ^\]2Q*Q*$E].!)Z8Q8$C>$)#)_&M
M17_+XZ.L<$IFSCB#RP0!GIO<2*("&CV1*:OT>\UQE9:N#/2]5]45J NC]EE]
M?^NP?70AD0'\%$<\5F0:-YKA6-.$'PM;^J!<:J#]\<-"H>-B"4I4Y.A4M%4\
M5A -9*J= P)J)S:<<&,YS $;BB6-#SGH=*<\+:FF?Z*K2N4AKE,G;UD+@+W!
MPA=8XM%,3),Y0719 %KT2A+RQ*@\><6C5SO4/:];1O^W2%&QZ'.!8_D" "_]
M-# =AYZH2LC T:I+&9T>K9@R?J^%;& 0US;C>DRY*&_T8#A/%"RPC$?2Y:(V
MG91=TQQC/'0[JT@.J\,Q(T8G>F,\5,7AWXZ4Z)=)Q0/JP6]Q.G]3NIA3A@BB
MEPYL?__]RV](7SU_3%\]IJ_^L?,%GFK?/C7F"A4>G?53G>X=&]@?\Y8_6I<+
M>ZC$' O,0[$SUM11%8>?G>T'^+<3_ZBN?-3R%0YH/'WHX8=_@Z'B'I=40MA-
MR8!R?#-G9""HMB"%')ISCQ7>0T685E-DTU=1X=NL3N''F'VU2Y2M5.Q'Y#-W
M7[_>KMDG,'#@MX(_#.I2IYKK$M^0 N9"1>^:LIX&0QQ"_[FBP?J+::K1Y74S
M2&6%H?(3;\$=JOI/\$WK!:#\6"$#PGM\TQ%$*X"(_5;AX(ZBK]J)7JT=K55-
MS:9>B=KL@+D2=:I+Y%&/92YL18CG"H@W*2_C=F[#(7Y<)6.,==X%H7U"7L9_
M!H&#WX^*11'C2ERI63TYM./K>C)\ 07FC<"=B\IL7S5D/1#NE@K88'970(SE
MJ>MK7)^Z4Z&CPH0A5V_!=:KY2ISWP;$+BCJ^@M<&L1&Z+V1:^.U%3HG;Q0=D
M ]S4H:)9<>BT:I_[1:S#D\0TR<I+(43]Y;3[\%')I8O?#%6"?0.+'T/(G\2+
M'X:ZJ.J%+.4WA+K%Z]&P13A];^'SL9')XF=XQI\M[0B/O?01-B(O?H@];,M0
ME2'TTN7@'FE\_^3"YYC"7OIL#A/$*S08Q6.=4H$VI0C!@0!"]!D4&Z?)G:K3
M46?7.#-&6.VN^&Y\1Y5%+9ISD1(6T.&6P$X%C^XO*-?I*,6(624]&L'^2 C+
M>7:?8\'R!ZM&"==8XV0IY(YJ\U9(40-LK.=J(N9#$W[ (<(SIS>H4DQRX\AJ
MGF=AK*G) #*]8VLI%\&)@?GD-JSA\5)[#Q4&6PN7U;7KPF. "?FSX+([,&QS
M?3>2V\=(]159-<<1C!A0(/.X!XX3TF*O$F%U\?TSQJMN',W$:.*1NO0BA44H
M5RM>VL("F!J#@')])$Z5_H5]_+L2RK$=^!G>.@)=3(_*U7OA8[ =LD8HKYMB
M6XR7B&0B/C[QU?]^*A:?(ZRO\70LOA+)P7CAEB)^=P61E>:;+Q)VAM LG%@@
M<&ADAYQ+Q1DB@3W+Z5*,,4'O)XJX=X]>'43OF9IOG_*7UE;%"5$Z\B][JL.'
M'4YV]?T[A$9Z,TD95_E#!-\6 <A#G92@.!5(GBG695H:M%(J ?S,:I5CI$]O
M=_;&+^2X(AIQ-6?S:G>#)V39\"%;A$ZRQ21!U0_(8YY6F)MJ24F&Q@7R#PN'
MF0X7FK)Q@BGZ(GC X2\9%;XYPF)9QBWR%UK_T$X'I;J^1BR':X,I!32;*<8P
MS*B8E03:11-4)&#H;#'U1<K!B#*\7]2#"&VL7&3UD#D&[[M$EGPG(\*EXR-/
MXI;81 4KV7J=\0A],J\A*9=B^"<]%\W]JCQ'*K_]##!GP#"'&'IS1NAI__CP
M69WL_#HWLKFX?ERNMKX&E\YE63@WD\LK6#\SH#.2X)R&8:\1X(E?#"?XS8^W
M. %(0\6F!^ %(M"0+BO)9?2:"Z0!O6AZ[>+\ U=W8TV^EQ).Z=_4#YY:Y42#
MB@U=.0[L1E/Q['V/MTK=.?=@TUK0$N7WOE[V)+NF)!A6]M[9HOT<NZK$!]1.
MUIGLQZ1C[W#5WHN7G5<O7G0VN]WG=\DGG_;<)"#A7\LIK_O,&&=@[N1=,L69
MO@*RJ9FRNP=8)-N7J3BPYB83]!K;#S3*!-^(14JQR,(8,+YZJ]OKO'[1[?2V
M-WO\"2 7EZ05_^5D.L2U'@)FZ^.U15]:&6D<L@B6")0LQ-W_AI4*L)/\PQ5V
M+"[<+)I0(-[;['4A^'C=>]/MO7S5[O9>O;K?JO(;$J?;.^(C&^XWXA03TO<F
MC_IPDIJWO,)[9;)NX^#CT1\H01L?!F>G>_\+4$L! A0#%     @ "S@J6@B-
MB2\N P  Z0L  !$              ( !     '!A<V<M,C R-3 Q,#@N>'-D
M4$L! A0#%     @ "S@J6FPZK%']"@  @(8  !4              ( !70,
M '!A<V<M,C R-3 Q,#A?;&%B+GAM;%!+ 0(4 Q0    (  LX*EKR#]7D60<
M -E7   5              "  8T.  !P87-G+3(P,C4P,3 X7W!R92YX;6Q0
M2P$"% ,4    "  +."I:=(%BX HD  #"R   $0              @ $9%@
M=&TR-3(W,CAD,5\X:RYH=&U02P$"% ,4    "  +."I:&3XH_GT:  "\A
M%0              @ %2.@  =&TR-3(W,CAD,5]E>#DY+3$N:'1M4$L%!@
0   %  4 1P$   )5      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm252728d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pasg-20250108.xsd" xlink:type="simple"/>
    <context id="AsOf2025-01-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2025-01-08</startDate>
            <endDate>2025-01-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-01-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-01-08" id="Fact000004">0001787297</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-01-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-01-08" id="Fact000010">2025-01-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-01-08" id="Fact000011">PASSAGE BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-01-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-01-08" id="Fact000013">001-39231</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-01-08" id="Fact000014">82-2729751</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-01-08" id="Fact000015">One     Commerce Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-01-08" id="Fact000016">2005 Market Street, 39th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-01-08" id="Fact000017">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-01-08" id="Fact000018">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-01-08" id="Fact000019">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-01-08" id="Fact000020">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-01-08" id="Fact000021">866-0311</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-01-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-01-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-01-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-01-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-01-08" id="Fact000026">Common     Stock, $0.0001 Par Value Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-01-08" id="Fact000027">PASG</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-01-08" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-01-08" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-01-08" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
